<DOC>
	<DOCNO>NCT00101413</DOCNO>
	<brief_summary>The purpose study evaluate BAY43-9006 effect tumor , long effect continue , patient receive BAY43-9006 live longer . - If BAY43-9006 effect quality life patient non-small cell lung cancer . - If BAY43-9006 help slow worsen non-small cell lung cancer . - If BAY43-9006 prevents growth , shrink non-small cell lung tumor and/or metastasis .</brief_summary>
	<brief_title>BAY43-9006 - Phase II Study Non-Small Cell Lung Carcinoma ( NSCLC )</brief_title>
	<detailed_description>In addition key secondary outcome parameter several potential biomarkers evaluate exploratory parameter . Issues safety address Adverse Event section . The following acronym abbreviation use Adverse Event section Limitations Caveats section : - gastrointestinal ( GI ) - otherwise specify ( NOS ) - central nervous system ( CNS ) - National Cancer Institute Common Terminology Criteria ( NCI-CTC ) - Medical Dictionary Regulatory Activities ( MedDRA ) - System Organ Class ( SOC ) - interim analysis ( IA )</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Age = 18 year Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 , 1 2 Life expectancy least 12 week pretreatment evaluation Patients metastatic , measurable , histologically cytologically document NSCLC ( include squamous , large cell adenocarcinoma ) . In case unique metastatic site , histological confirmation require order ensure proper diagnosis prior study entry Patients must progressive nonsmall cell lung cancer ( NSCLC ) No 2 prior systemic agent regimen least 28 day prior study entry . ( Prior therapy gefitinib allow mandatory ) Patients must consider appropriate systemic anticancer therapy Investigator Patients least one unidimensional measurable lesion compute tomography ( CT ) scan magnetic resonance imaging ( MRI ) accord Response Evaluation Criteria Solid Tumors ( RECIST ) Adequate bone marrow , liver renal function , assess follow laboratory : Hemoglobin = 9.0 g/dl Absolute granulocytes = 1.5 x 10E9/L Platelet count = 100 x 10E9/L Total bilirubin &lt; 1.5 x upper limit normal alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &lt; 2.5 x upper limit normal ( &lt; 5 x upper limit normal patient liver involvement cancer ) prothrombin time ( PT ) International Normalized Ratio ( INR ) partial thromboplastin time ( PTT ) &lt; 1.5 x upper limit normal ( except patient warfarin heparin . Patients receive anticoagulation treatment agent warfarin heparin , prophylactically therapeutically , allow participate . For patient warfarin , close monitoring least weekly evaluation perform INR stable base measurement pre dose , define local standard care ) Serum creatinine = 2.0 x upper limit normal Amylase lipase &lt; 1.5 x upper limit normal Cardiac arrhythmia require antiarrhythmic ( exclude betablockers digoxin ) , symptomatic coronary artery disease ( CAD ) ischemia ( myocardial infarction ( MI ) within last 6 month ) congestive heart failure ( CHF ) &gt; New York Heart Association ( NYHA ) Class II Uncontrolled hypertension Complete renal shutdown require hemo peritoneal dialysis Mixed histology Active clinically serious infection ( &gt; grade 2 National Cancer Institute [ NCI ] Common Terminology Criteria Adverse Events ( CTCAE ) Version 3.0 ) Known history HIV infection chronic hepatitis B C Known metastatic brain meningeal tumor , unless patient &gt; 6 month definitive therapy , negative imaging study within 4 week study entry clinically stable respect tumor time study entry . A head CT MRI must conduct rule brain metastasis meningeal tumor . Also patient must undergo acute steroid therapy taper ( chronic steroid therapy acceptable , provide dose stable one month prior follow screen radiographic study ) History seizure disorder require medication ( steroids antiepileptic ) History organ allograft bone marrow transplant Previous malignancy ( except cervical carcinoma situ , adequately treat basal cell carcinoma , superficial bladder tumor [ Ta , Tis &amp; T1 ] malignancy curatively treat &gt; 3 year prior entry ) Patients clinically significant bleeding ( e.g. , gastrointestinal bleeding ) within past month prior study entry ineligible Pregnant breastfeeding patient . Women childbearing potential must negative pregnancy test perform within 7 day start treatment . Both men woman enrol trial must use adequate barrier birth control measure ( e.g . cervical cap , condom , diaphragm ) course trial . Oral birth control method alone consider adequate study , potential pharmacokinetic interaction BAY 439006 oral contraceptive Substance abuse , medical , psychological social condition , judgment investigator , likely interfere patient participation study evaluation study result Known allergy investigational agent agent give association trial Any condition unstable could jeopardize safety patient compliance study , investigator 's judgment Anti cancer chemotherapy , immunotherapy , vaccine investigational therapy study within 4 week study entry . Radiotherapy study within 4 week study entry . Patients must recover radiationinduced toxicity . However , palliative allow local pain control . Any surgical procedure within 4 week prior start study drug . Autologous and/or allogenic include miniallogenic bone marrow transplant stem cell rescue . Use biologic response modifier , GranulocyteColony Stimulating Factor ( GCSF ) Granulocyte macrophage colonystimulating factor ( GMCSF ) , within 3 week study entry . GCSF hematopoietic growth factor may use management acute toxicity , medically indicate , discretion investigator . Patients take chronic erythropoietin permit provide dose adjustment undertaken within 2 month prior study study . Use St. John 's Wort . Use rifampicin . Prior use RafKinase inhibitor , MAPK/ERK kinase ( MEK ) Farnesyl Transferase Inhibitors . Prior use Bevacizumab drug target vascular endothelial growth factor ( VEGF ) / vascular endothelial growth factor receptor ( VEGFR ) . Use investigational drug therapy outside within 4 week study entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>NSCLC</keyword>
</DOC>